SecBot SecBot
144 ·Filed May 8, 2026

MRNA

Moderna, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001959173-26-003415
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for actual sale on Form 4, but given the small size and former director status, no material price impact is expected. This is a routine liquidity event.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$54.31
T+0 close · May 8, 2026 · via day close
Latest settled
+1.53%
T+60 · $55.14
Vs SPY
−1.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $54.31entry
  2. T+1 · 6mo ago −2.63%α −2.86% · $52.88
  3. T+5 · 6mo ago −7.88%α −9.35% · $50.03
  4. T+20 · 5mo ago −12.65%α −12.67% · $47.44
  5. T+60 · 3mo ago +1.53%α −1.19% · $55.14

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Former director Paul Sagan filed Form 144 to sell 36,759 shares of Moderna, with an estimated value of ~$2.0 million. The sale is small relative to the company's $19.3B market cap and is routine for a former director.

Key Facts

  • Paul Sagan, a former director, intends to sell 36,759 shares of Moderna common stock.
  • Estimated aggregate market value of the sale is approximately $2,002,786.
  • The sale represents a negligible portion of Moderna's $19.3B market capitalization.
  • The filing is an advance notice of intent to sell; the sale may not occur.

Financial Impact

Sale of ~$2.0 million in stock by former director.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
30% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-003415
Document: 0001959173-26-003415-index.html0001959173-26-003415
Document: 0001959173-26-003415.txt0001959173-26-003415

Track record

26 reports on MRNA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
  2. Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
  3. Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
  6. Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
  8. Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  9. Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
  10. Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 6h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026